Cargando…
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
BACKGROUND: Elevated cerebrospinal fluid (CSF) concentrations of total tau (T-tau) and phosphorylated tau at Thr181 (P-tau181) protein are typical of Alzheimer’s disease (AD). However, the T-tau assay measures only the mid-region of the protein, while tau in CSF is instead composed of a series of fr...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871566/ https://www.ncbi.nlm.nih.gov/pubmed/33557920 http://dx.doi.org/10.1186/s13195-020-00756-6 |
_version_ | 1783649032316387328 |
---|---|
author | Cicognola, Claudia Hansson, Oskar Scheltens, Philip Kvartsberg, Hlin Zetterberg, Henrik Teunissen, Charlotte E. Blennow, Kaj |
author_facet | Cicognola, Claudia Hansson, Oskar Scheltens, Philip Kvartsberg, Hlin Zetterberg, Henrik Teunissen, Charlotte E. Blennow, Kaj |
author_sort | Cicognola, Claudia |
collection | PubMed |
description | BACKGROUND: Elevated cerebrospinal fluid (CSF) concentrations of total tau (T-tau) and phosphorylated tau at Thr181 (P-tau181) protein are typical of Alzheimer’s disease (AD). However, the T-tau assay measures only the mid-region of the protein, while tau in CSF is instead composed of a series of fragments. One fragment species in particular, N-224, shows increased levels in AD compared to controls. In this multicentre study, we performed a clinical validation of the N-224 assay in cohorts including patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), AD, non-AD dementias and controls. METHODS: Cohorts consisted of 30 SCD and 30 probable AD from the Amsterdam Dementia Cohort (cohort 1) and 539 controls, 195 SCD, 232 MCI, 137 AD and 253 non-AD from the Swedish BioFINDER study (cohort 2). All samples had AD core biomarkers (Aβ42, T-tau, P-tau181) measurements. N-224 was measured with an in-house ultrasensitive Simoa assay. RESULTS: N-224 levels were significantly higher in AD compared to SCD (cohort 1: p = 0.003) and in AD compared to all other diagnostic groups in cohort 2 (control, SCD, MCI and non-AD, p < 0.0001). Within the non-AD group, N-224 showed significantly lower concentrations compared to AD in Parkinson’s disease (PD, p < 0.0001), Parkinson’s disease dementia (PDD, p = 0.004), progressive supranuclear palsy (PSP, < 0.0001), multiple system atrophy (MSA, p = 0.002) and parkinsonisms not otherwise specified (NOS, p = 0.007). In cohort 1, higher concentrations of N-224 were associated to lower Mini-Mental State Examination (MMSE) scores (R(2) = 0.318, β = 0.564, p ≤ 0.0001) and could accurately identify a pathological (< 24) MMSE score (p < 0.0001, AUC = 0.824). CONCLUSIONS: N-224 tau can distinguish AD subjects from SCD and can discriminate subgroups of non-AD dementias from AD. Therefore, N-224 may be a useful addition to the tau biomarker toolbox for the study of tau species in CSF and for better understanding disease pathogenesis. |
format | Online Article Text |
id | pubmed-7871566 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-78715662021-02-09 Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias Cicognola, Claudia Hansson, Oskar Scheltens, Philip Kvartsberg, Hlin Zetterberg, Henrik Teunissen, Charlotte E. Blennow, Kaj Alzheimers Res Ther Research BACKGROUND: Elevated cerebrospinal fluid (CSF) concentrations of total tau (T-tau) and phosphorylated tau at Thr181 (P-tau181) protein are typical of Alzheimer’s disease (AD). However, the T-tau assay measures only the mid-region of the protein, while tau in CSF is instead composed of a series of fragments. One fragment species in particular, N-224, shows increased levels in AD compared to controls. In this multicentre study, we performed a clinical validation of the N-224 assay in cohorts including patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), AD, non-AD dementias and controls. METHODS: Cohorts consisted of 30 SCD and 30 probable AD from the Amsterdam Dementia Cohort (cohort 1) and 539 controls, 195 SCD, 232 MCI, 137 AD and 253 non-AD from the Swedish BioFINDER study (cohort 2). All samples had AD core biomarkers (Aβ42, T-tau, P-tau181) measurements. N-224 was measured with an in-house ultrasensitive Simoa assay. RESULTS: N-224 levels were significantly higher in AD compared to SCD (cohort 1: p = 0.003) and in AD compared to all other diagnostic groups in cohort 2 (control, SCD, MCI and non-AD, p < 0.0001). Within the non-AD group, N-224 showed significantly lower concentrations compared to AD in Parkinson’s disease (PD, p < 0.0001), Parkinson’s disease dementia (PDD, p = 0.004), progressive supranuclear palsy (PSP, < 0.0001), multiple system atrophy (MSA, p = 0.002) and parkinsonisms not otherwise specified (NOS, p = 0.007). In cohort 1, higher concentrations of N-224 were associated to lower Mini-Mental State Examination (MMSE) scores (R(2) = 0.318, β = 0.564, p ≤ 0.0001) and could accurately identify a pathological (< 24) MMSE score (p < 0.0001, AUC = 0.824). CONCLUSIONS: N-224 tau can distinguish AD subjects from SCD and can discriminate subgroups of non-AD dementias from AD. Therefore, N-224 may be a useful addition to the tau biomarker toolbox for the study of tau species in CSF and for better understanding disease pathogenesis. BioMed Central 2021-02-08 /pmc/articles/PMC7871566/ /pubmed/33557920 http://dx.doi.org/10.1186/s13195-020-00756-6 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Cicognola, Claudia Hansson, Oskar Scheltens, Philip Kvartsberg, Hlin Zetterberg, Henrik Teunissen, Charlotte E. Blennow, Kaj Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias |
title | Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias |
title_full | Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias |
title_fullStr | Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias |
title_full_unstemmed | Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias |
title_short | Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias |
title_sort | cerebrospinal fluid n-224 tau helps discriminate alzheimer’s disease from subjective cognitive decline and other dementias |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871566/ https://www.ncbi.nlm.nih.gov/pubmed/33557920 http://dx.doi.org/10.1186/s13195-020-00756-6 |
work_keys_str_mv | AT cicognolaclaudia cerebrospinalfluidn224tauhelpsdiscriminatealzheimersdiseasefromsubjectivecognitivedeclineandotherdementias AT hanssonoskar cerebrospinalfluidn224tauhelpsdiscriminatealzheimersdiseasefromsubjectivecognitivedeclineandotherdementias AT scheltensphilip cerebrospinalfluidn224tauhelpsdiscriminatealzheimersdiseasefromsubjectivecognitivedeclineandotherdementias AT kvartsberghlin cerebrospinalfluidn224tauhelpsdiscriminatealzheimersdiseasefromsubjectivecognitivedeclineandotherdementias AT zetterberghenrik cerebrospinalfluidn224tauhelpsdiscriminatealzheimersdiseasefromsubjectivecognitivedeclineandotherdementias AT teunissencharlottee cerebrospinalfluidn224tauhelpsdiscriminatealzheimersdiseasefromsubjectivecognitivedeclineandotherdementias AT blennowkaj cerebrospinalfluidn224tauhelpsdiscriminatealzheimersdiseasefromsubjectivecognitivedeclineandotherdementias |